Rise in Use of Non-Liver Tox Studies May Help Pharma Avoid Side Effects | GenomeWeb

NEW ORLEANS — Could a non-hepatic toxicogenomic profile have prevented the problems experienced by drugs such as Vioxx?

The use of toxicogenomic profiling in non-hepatic tissue is on the rise among drug makers in the United States, according to industry experts interviewed for this article. But few companies are willing to talk about the ways in which they are using these tools in their own R&D, and those that use them oftentimes do so narrowly.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.